Scientia Ventures

Scientia follows a dual-track model: it builds new companies around innovations its team identifies internally, and it partners with existing companies to accelerate growth and commercialization. The firm's partners draw on their own operating and scientific networks to source deals. This blend of venture formation and traditional early-stage investing gives it a proprietary pipeline concentrated on breakthroughs in computational biology and drug development.

The firm invests at the early-to-mid stage, spanning seed, start-up, and subsequent clinical and commercial inflection points. Its portfolio includes companies at various stages, from pre-revenue drug developers to publicly traded royalty platforms like Royalty Pharma. The focus remains on novel life-science technologies with the potential for radical change.

Scientia concentrates exclusively on healthcare, with a specific emphasis on computational biology and chemistry, the digitization of medicine, traditional drug development, and, through Cibus, precision gene editing for agriculture. It does not invest outside life-science and adjacent agri-tech applications.

Yes. The firm notes five IPOs from its 31-company portfolio. Named public portfolio holdings include Royalty Pharma, ADC Therapeutics, and Intra-Cellular Therapies. These exits span the royalty-financing, oncology, and neuroscience subsectors.

Scientia makes direct equity investments through its fund vehicles rather than committing capital as a limited partner to other venture funds. Its strategy is built around active involvement in the strategic and commercial direction of the companies it backs, which aligns with a direct-only, active-management posture.

Scientia does not publicly name its individual partners or investment committee. It describes its team collectively as a group with domain expertise across healthcare, finance, and intellectual property, many of whom are former life-science founders, operators, and CEOs. Decision-making authority and internal committee structure are not disclosed.

The firm does not disclose its AUM, fund sizes, or limited partner base. It states that its investors and general partners take a long-term view, but no specific institutional, family-office, or individual backers have been publicly identified. Its fund structure — at least three sequential funds — suggests repeat institutional or private capital commitments.